Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Intrance Medical Systems

Request full access

A private biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson’s disease (a subsidiary of Intrance Holdings…

New York City, United StatesFounded 2018Biotech & Life Sciences

About Intrance Medical Systems

Intrance Medical Systems, Inc. operates as a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for advanced Parkinson’s disease (APD). Established in 2018, the firm was an independent spin-out from the Sweden-based Lobsor Pharmaceuticals AB. The company's efforts are concentrated on bringing its lead product to markets including the U.S., Canada, South America, Japan, and Taiwan, where it holds all intellectual property and commercial rights.

The company's history is rooted in the extensive experience of its founders, Ulf Rosén and Roger Bolsöy. Both held key executive roles at companies like NeoPharma, Solvay, and AbbVie, where they were involved in the development and commercialization of a levodopa-carbidopa intestinal gel, a recognized therapy for APD. Leveraging this background, they founded Lobsor Pharmaceuticals and developed a patented gel formulation in 2013 to address unmet needs in APD treatment. This led to the creation of Intrance Medical Systems to handle commercialization in specific international markets. In September 2020, STADA's Britannia Pharmaceuticals acquired Lobsor, while Intrance retained its specified territorial rights.

Intrance Medical Systems is advancing a drug-device combination therapy, known in Europe as Lecigon®. This product is a fixed-dose gel formulation combining three active substances: levodopa, carbidopa, and entacapone. It is designed for continuous enteral infusion directly into the small intestine via a lightweight, wearable pump. This method of delivery bypasses the stomach, which can be beneficial as oral medication can become less effective in the later stages of Parkinson's due to issues like erratic gastric emptying. The addition of entacapone to the formula increases the bioavailability of levodopa, which allows for lower doses and the use of a smaller pump, weighing just 134 grams, enhancing patient convenience.

The company's business model centers on gaining regulatory approval and commercializing this specialized therapy for patients with advanced Parkinson's disease. Lecigon® has already been approved and is commercially available in several European countries, where it has seen positive market uptake. To fund its U.S. clinical development program, Intrance completed a Series A financing round in 2022, raising a total of $17 million, with notable investors including Erik Selin and Rutger Arnhult. The company has received FDA clearance for its Investigational New Drug (IND) application and is proceeding with its clinical trials in the United States.

Source: Dealroom company data

At a glance

Status
Operational
Employees
7
Open positions
None listed
Dealroom signal
56.8/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jan 2022 $17M $68M Rutger Arnhult · Erik Selin ↗
SERIES A✓Equity / VC Nov 2021 $3M $40M Rutger Arnhult ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Intrance Medical Systems website traffic

Latest recorded traffic for Intrance Medical Systems is 1.7K monthly website visits, up 304.8% over the last three months. Intrance Medical Systems's team grew 40% over the past year.

Latest monthly visits1.7K 3-month web change+304.8% 1-year team growth+40%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
CaroCure Discovery Solutions Private LimitedPreclinical drug discovery cro that uses computational chemistry and ai to develop new drugs and cosmetics Hyderabad, India Operational 1 $700K —
Contraria BiotechDevelops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics Siena, Italy Operational
Synkrino BiotherapeuticsLeverages deep industry experience and technical expertise to pinpoint early-stage ventures in under-served healthcare sectors where significant ongoing support can maximize efficiencies and produce superior returns St. Louis, United States Operational
Ochre BioDevelops RNA therapies for chronic liver diseases, a leading cause of death globally Oxford, United Kingdom Operational
BigHat BiosciencesProtein therapeutics company that develops an antibody design platform guided by artificial intelligence San Carlos, United States Operational
XilisDeveloping next generation technologies for precision medicine and drug discovery Durham, United States Operational
MindRank AIMindRank AI is a developer of proprietary end-to-end AI-driven drug-discovery platform (Molecule Pro™) Hangzhou, China Operational
Rosa BiotechAI-driven biosensing and diagnostics company providing outcome-focused biosensing for early disease diagnosis and for use in industrial biotechnology Bristol, United Kingdom Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Intrance Medical Systems in the New York City ecosystem

Live from Dealroom

The Intrance Medical Systems office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Erik Selin
  • Rutger Arnhult

Other known investors1 additional known investor

  • M2 Asset Management AB
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States66.7%
🇸🇪 Sweden33.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Intrance Medical Systems on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Intrance Medical Systems’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.